Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371861 | 0.86 | MET (0.51) | METFLT3KDRPDGFRAEGFR | |
| SCHEMBL168001 | 0.81 | AXL (0.54) | METFLT3KDRAXL | |
| SCHEMBL168510 | 0.78 | MET (0.47) | METKDRPDGFRAKIT | |
| SCHEMBL20216630 | 0.77 | KDR (0.52) | METFLT3KDRPDGFRAKIT | |
| SCHEMBL15918385 | 0.76 | MET (0.70) | METFLT3KDRPDGFRAKIT | |
| SCHEMBL3542937 | 0.76 | MET (0.56) | METFLT3KDRPDGFRAEGFR | |
| SCHEMBL3542938 | 0.76 | MET (0.56) | METFLT3KDRPDGFRAEGFR | |
| SCHEMBL14315648 | 0.76 | PDE4A (0.47) | METKDRPDGFRA | |
| SCHEMBL374524 | 0.76 | AXL (0.52) | METFLT3KDRPDGFRADNMT3A | |
| SCHEMBL1475840 | 0.76 | GAA (0.54) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | MET 3/4885FLT3 7/4885KDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.